Revvity introduces EONIS Q system enabling faster, simplified newborn screening for SMA and SCID
Revvity has launched its EONIS Q system, a CE-IVD marked platform enabling laboratories in countries that accept the CE marking to adopt molecular testing for spinal muscular atrophy (SMA) and severe combined immunodeficiency (SCID) in newborns.